Summit Therapeutics plc Appointment Of Joint Broker

 
TIDMSUMM 
 
   Summit Therapeutics plc 
 
   ('Summit' or the 'Company') 
 
   Appointment of Joint Broker 
 
   Oxford, UK, and Cambridge, MA, US, 12 November 2018 -- Summit 
Therapeutics plc (NASDAQ: SMMT, AIM: SUMM), a leader in new mechanism 
antibiotic innovation, announces that it has with immediate effect 
appointed Bryan Garnier & Co. Limited as its joint broker.  N+1 Singer 
remains joint broker and Cairn Financial Advisers remains the Company's 
Nominated Adviser. 
 
   About Summit Therapeutics 
 
   Summit Therapeutics is a leader in antibiotic innovation. Our new 
mechanism antibiotics are designed to become the new standards of care 
for the benefit of patients, and create value for payors and healthcare 
providers. We are currently developing new mechanism antibiotics for C. 
difficile infection and gonorrhoea and are using our proprietary Discuva 
Platform to expand our pipeline. For more information, visit 
www.summitplc.com and follow us on Twitter @summitplc. 
 
   Contacts 
 
 
 
 
Summit 
Glyn Edwards / Richard Pye (UK office)          Tel:               44 (0)1235 443 951 
Erik Ostrowski / Michelle Avery (US office)                           [phone] 
 
Cairn Financial Advisers LLP (Nominated 
 Adviser)                                       Tel:              [phone] 
Liam Murray / Tony Rawlinson 
 
N+1 Singer (Joint Broker)                       Tel:              [phone] 
Aubrey Powell / Jen Boorer, Corporate Finance 
 Tom Salvesen, Corporate Broking 
 
Bryan Garnier & Co Limited (Joint Broker)       Tel:              [phone] 
Phil Walker / Dominic Wilson 
 
MSL Group (US)                                  Tel:                  [phone] 
                                                           mailto:[e-mail] 
Jon Siegal                                                        [e-mail] 
                                                       ------------------------------ 
 
Consilium Strategic Communications (UK)         Tel:              [phone] 
Mary-Jane Elliott / Jessica Hodgson /                  mailto:summit@consilium-comms. 
                                                       com 
                                                       [e-mail] 
                                                       ------------------------------ 
Lindsey Neville 
 
 
   -END- 
 
 
 
 
 
 

(END) Dow Jones Newswires

November 12, 2018 02:00 ET (07:00 GMT)

Copyright (c) 2018 Dow Jones & Company, Inc.